4 million1 hours of hypoglycemia avoided Trust in the algorithm leads to fewer meal declarations Users report a significantly reduced mental load (PRESS RELEASE) PARIS, 21-Sep-2022 — /EuropaWire/ — Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports … Read the full press release
Posted in Denmark, France, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology
Tagged #dedoc, automated insulin delivery, DBL-4pen, DBL-hu, DBLG1, Diabeloop, Diabetes, EASD, EASD Annual Meeting 2022, EASD2022, Erik Huneker, hybrid closed-loop system, Hypoglycemia, insulin delivery, Pr. Lutz Heinemann, Pr. Pierre-Yves Benhamou, Stéphanie JEGU, therapeutic AI, Time In Range, type 1 diabetes
EASD 2021 – Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, is presenting new real-world data(1) of its Automated Insulin Delivery system, DBLG1. The personalized device fine-tunes insulin delivery using a state-of-the-art algorithm. Thousands of European patients have … Read the full press release
Posted in Artificial Intelligence (AI), France, Healthcare, Italy, News, Pharma & Biotech, Science, Spain, Technology
Tagged ACCU-CHEK, Accu-Chek Insight, algorithm, artificial-intelligence, Automated Insulin Delivery system, CE certificate, CGM, continuous glucose monitor, data, data visualization platform, DBLG1, DBLG1 System, Dexcom, Dexcom G6, Diabeloop, Diabetes, EASD 2021, Erik Huneker, glucose, HbA1c, Hypoglycemia, Insulin Pump, Pr. Pierre-Yves Benhamou, Roche, Stéphanie JEGU, T1D, therapeutic artificial intelligence, therapeutic artificial intelligence for diabetes management, Time In Range, TÜV Rheinland, type 1 diabetes, YourLoops
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
